title: Platinum cytostatics influence--the primary antibody response of mouse spleen cells in vitro.
abstract: The effects of three platinum containing cytostatic drugs--cis-DDP, CBDCA, and OXO--on in vitro primary antibody production after the treatment of mouse spleen cells with these compounds were studied. The technique of Marbrook was employed, the antibody response was assessed according to the number of plaque-forming cells (PFC) after the antigenic stimulation by sheep red blood cells (SRBC) in vitro. All of the three platinum complexes studied had inhibitory effect on antibody response at concentrations of 1 X 10(-5) to 1 X 10(-7) mol/l without affecting the viability of the mouse spleen cells. A comparison of the effectiveness of the three cytostatic drugs showed that cis-DDP was the most potent inhibitor. To obtain a similar inhibitory effect with CBDCA and OXO, concentrations 10 times as high as that in cis-DDP were required, depending on the time relation to antigenic stimulation. The lowest inhibitory effect on antibody production was observed in CBDCA. These drugs acted either after a simultaneous administration or 48 h after the antigen, i.e., at the time of maximal proliferation and differentiation of the cells. DNA synthesis must undoubtedly have been affected as well.
authors.forename: M
authors.initials: M
authors.lastname: Vancurová
authors.forename: J
authors.initials: J
authors.lastname: Procházková
authors.forename: M
authors.initials: M
authors.lastname: Nováková
authors.forename: Z
authors.initials: Z
authors.lastname: Blahuta
mesh_terms: D000818:Animals; D000917:Antibody Formation / Q000187:drug effects*; D016190:Carboplatin; D002470:Cell Survival; D002945:Cisplatin / Q000031:analogs & derivatives* / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008808:Mice, Inbred CBA; D009944:Organoplatinum Compounds / Q000494:pharmacology*; D013154:Spleen / Q000187:drug effects*
chemical_list: D009944:Organoplatinum Compounds; D016190:Carboplatin; D002945:Cisplatin; C043804:diamminedichlorodihydroxyplatinum IV